在一名转移性食管癌患者中，卡培他滨和奥沙利铂在纳武单抗治疗后诱发了史蒂文斯-约翰逊综合征。
Capecitabine and oxaliplatin induced Steven-Johnson syndrome following nivolumab in a patient of metastatic esophageal carcinoma.
作者信息
Kumar Sumit, Nongkynrih Anthialisha, Dey Biswajit, Jagtap Vikas, Lamba Reena, Chyrmang Deiwakor
机构信息
Department of Radiation Oncology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Oncology OPD room No 215, Mawdiangdiang, East Khasi Hills District, Shillong, Meghalaya 793018 India.
Department of Pathology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Shillong, Meghalaya India.
出版信息
Int Cancer Conf J. 2024 Feb 29;13(2):167-170. doi: 10.1007/s13691-024-00660-y. eCollection 2024 Apr.
Abstract
Stevens-Johnson syndrome presents as mucocutaneous blistering and sloughing, which may follow a devastating clinical course. Although Stevens-Johnson syndrome has been reported following the administration of anticancer drugs, only a few cases induced by cytotoxic anticancer drugs, administered after immune checkpoint inhibitors, have been reported. The present report describes a case of Stevens-Johnson syndrome caused by capecitabine and oxaliplatin (CAPEOX) combination chemotherapy, in a patient with esophageal squamous cell carcinoma, who had been previously treated with nivolumab.
摘要
史蒂文斯-约翰逊综合征表现为皮肤黏膜水疱和脱落，其临床过程可能很严重。虽然已有使用抗癌药物后发生史蒂文斯-约翰逊综合征的报道，但免疫检查点抑制剂治疗后使用细胞毒性抗癌药物诱发的病例仅有少数报道。本报告描述了1例食管鳞状细胞癌患者在接受纳武单抗治疗后，因卡培他滨和奥沙利铂（CAPEOX）联合化疗引起史蒂文斯-约翰逊综合征的病例。
相似文献
1
Capecitabine and oxaliplatin induced Steven-Johnson syndrome following nivolumab in a patient of metastatic esophageal carcinoma.在一名转移性食管癌患者中，卡培他滨和奥沙利铂在纳武单抗治疗后诱发了史蒂文斯-约翰逊综合征。
Int Cancer Conf J. 2024 Feb 29;13(2):167-170. doi: 10.1007/s13691-024-00660-y. eCollection 2024 Apr.
2
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).纳武利尤单抗联合 S-1/卡培他滨加奥沙利铂治疗未经治疗的、不可切除的、晚期或复发性胃/胃食管结合部腺癌患者的安全性和有效性：一项随机、II 期试验（ATTRACTION-4）的中期结果。
Ann Oncol. 2019 Feb 1;30(2):250-258. doi: 10.1093/annonc/mdy540.
3
Capecitabine induced Steven-Johnson syndrome: A rare case report.卡培他滨引起的史蒂文斯-约翰逊综合征：一例罕见病例报告。
J Oncol Pharm Pract. 2022 Jan;28(1):250-254. doi: 10.1177/10781552211027945. Epub 2021 Jun 24.
4
Nivolumab-associated Stevens-Johnson syndrome in a patient with lung cancer.纳武利尤单抗相关的史蒂文斯-约翰逊综合征 1 例合并肺癌患者
Dermatol Online J. 2021 Mar 15;27(3):13030/qt2897t6dq.
5
Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome.纳武单抗诱导的史蒂文斯-约翰逊综合征放疗部位出现显著强化。
Dermatol Online J. 2018 Jun 15;24(6):13030/qt97g3t63v.
6
Lichenoid dermatitis preceding Stevens-Johnson syndrome in a patient treated with nivolumab.接受尼伏单抗治疗的患者出现斯蒂文斯-约翰逊综合征前的苔藓样皮炎。
BMJ Case Rep. 2022 Aug 26;15(8):e251233. doi: 10.1136/bcr-2022-251233.
7
[Experience of Using Immune Checkpoint Inhibitors and Chemotherapy in the Upper Gastrointestinal Tract at Our Hospital].[我院在上消化道疾病中使用免疫检查点抑制剂和化疗的经验]
Gan To Kagaku Ryoho. 2023 Aug;50(8):923-925.
8
Case Series of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Nivolumab and Nivolumab/ Ipilimumab Combination Therapy in Metastatic Melanoma.转移性黑色素瘤患者接受纳武利尤单抗及纳武利尤单抗/伊匹木单抗联合治疗后出现史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症的病例系列研究。
J Drugs Dermatol. 2022 May 1;21(5):529-530. doi: 10.36849/JDD.6559.
9
Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.一项关于晚期结直肠癌的随机 III 期临床试验方案：序贯卡培他滨或 5-氟尿嘧啶加贝伐单抗（Cape/5-FU-Bmab）对比卡培他滨或 5-氟尿嘧啶加奥沙利铂加贝伐单抗（CapeOX/mFOLFOX6-Bmab）与联合 CapeOX/mFOLFOX6-Bmab 的 C 立方（C3）研究
BMJ Open. 2016 Jun 2;6(6):e011454. doi: 10.1136/bmjopen-2016-011454.
10
Steven-Johnson Syndrome: A Rare but Serious Adverse Event of Nivolumab Use in a Patient With Metastatic Gastric Adenocarcinoma.史蒂文斯-约翰逊综合征：纳武利尤单抗用于一名转移性胃腺癌患者时发生的罕见但严重的不良事件。
J Med Cases. 2022 Sep;13(9):449-455. doi: 10.14740/jmc3992. Epub 2022 Sep 28.
引用本文的文献
1
Immune-related toxic epidermal necrolysis affecting trachea mucosal epithelium: a case report and literature review.免疫相关的中毒性表皮坏死松解症累及气管黏膜上皮：一例报告及文献复习
Front Pharmacol. 2024 Oct 18;15:1454015. doi: 10.3389/fphar.2024.1454015. eCollection 2024.
本文引用的文献
1
Steven-Johnson Syndrome: A Rare but Serious Adverse Event of Nivolumab Use in a Patient With Metastatic Gastric Adenocarcinoma.史蒂文斯-约翰逊综合征：纳武利尤单抗用于一名转移性胃腺癌患者时发生的罕见但严重的不良事件。
J Med Cases. 2022 Sep;13(9):449-455. doi: 10.14740/jmc3992. Epub 2022 Sep 28.
2
Clinical complete response after nivolumab administered as a third-line treatment for unresectable advanced gastric cancer with peritoneal dissemination: A case report.纳武利尤单抗作为不可切除的伴有腹膜播散的晚期胃癌三线治疗后的临床完全缓解：一例报告
Int J Surg Case Rep. 2021 Jul;84:106161. doi: 10.1016/j.ijscr.2021.106161. Epub 2021 Jun 30.
3
Capecitabine induced Steven-Johnson syndrome: A rare case report.卡培他滨引起的史蒂文斯-约翰逊综合征：一例罕见病例报告。
J Oncol Pharm Pract. 2022 Jan;28(1):250-254. doi: 10.1177/10781552211027945. Epub 2021 Jun 24.
4
Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review.史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症样反应的检查点抑制剂：系统评价。
Int J Dermatol. 2020 Jun;59(6):e183-e188. doi: 10.1111/ijd.14811. Epub 2020 Feb 13.
5
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.纳武利尤单抗对比化疗用于既往化疗后进展或不耐受的晚期食管鳞癌患者（ATTRACTION-3）：一项多中心、随机、开放标签、III 期临床研究。
Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30.
6
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.免疫检查点抑制剂治疗相关炎症性皮疹：毒性分层的单机构回顾性分析及其对治疗的影响。
J Am Acad Dermatol. 2019 Apr;80(4):990-997. doi: 10.1016/j.jaad.2018.10.062. Epub 2018 Nov 3.
7
Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.监测非小细胞肺癌患者纳武利尤单抗免疫动力学的临床意义。
JCI Insight. 2018 Oct 4;3(19):59125. doi: 10.1172/jci.insight.59125.
8
Durable response after discontinuation of nivolumab therapy in patients with metastatic renal cell carcinoma.纳武单抗治疗转移性肾细胞癌患者停药后的持久反应。
Jpn J Clin Oncol. 2018 Sep 1;48(9):860-863. doi: 10.1093/jjco/hyy106.
9
Management of Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis: Looking Beyond Guidelines!史蒂文斯-约翰逊综合征-中毒性表皮坏死松解症的管理：超越指南！
Indian J Dermatol. 2018 Mar-Apr;63(2):117-124. doi: 10.4103/ijd.IJD_583_17.
10
Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer.免疫检查点抑制剂：癌症患者治疗与管理中免疫疗法的一项创新。
Asia Pac J Oncol Nurs. 2017 Apr-Jun;4(2):127-135. doi: 10.4103/apjon.apjon_4_17.
Zotero 插件